Homoharringtonine Plus Androgen Deprivation Therapy in the Neoadjuvant Treatment of Prostate Cancer: A Single-Arm Clinical Study

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

93

Participants

Timeline

Start Date

September 20, 2025

Primary Completion Date

September 20, 2027

Study Completion Date

December 20, 2027

Conditions
Prostate Cancer
Interventions
DRUG

homoharringtonine

Intravenous infusion of 1mg homoharringtonine plus 250ml of 5% glucose injection, administered once daily for two consecutive days.

PROCEDURE

Radical prostatectomy

All patients will undergo radical prostatectomy within 3 weeks (±7 days) after the completion of treatment.

All Listed Sponsors
collaborator

The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China

OTHER

collaborator

Subei People's Hospital of Jiangsu Province

OTHER

collaborator

The First People Hospital of Nantong City

UNKNOWN

lead

baotai Liang

OTHER